ClinicalTrials.gg
RecruitingNCT07143981Updated Jan 23, 2026

The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa

An observational study in Anorexia Nervosa, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruiting at 1 site in Canada. Open to participants aged 16 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
16 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Anorexia Nervosa with a site in Canada — 7 open to participants now, 8 under way, none of them phase 3. Anorexia Nervosa · Canada.

Started
2026
with 2 others
Observational
2 of 21
1 open now
Registered
19th of 21
by date
Lead sponsor
1 of 21
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Among the 21 studies in Anorexia Nervosa with a site in Canada, this one is one of 3 that started in 2026, is one of 2 observational ones, and was the 19th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

7 of the 21 studies in Anorexia Nervosa with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 16 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Anorexia Nervosa with a site in Canada, or all of them as a file.
02

Study summary

Anorexia Nervosa (AN) is a severe, debilitating and potentially life threatening illness that is difficult to treat. A cardinal symptom of AN is the mistaken belief on the part of the individuals that they are overweight and must continue to restrict intake. This fixed false belief is a detrimental factor to recovery. It is known that AN involves disturbance in the gut microbiome (GM; the microbes that live in the lower intestinal tract). The GM also affects how one thinks and makes food choices - there appears to be a direct link between the GM and how the brain functions. This connection is thought to occur through chemical processes that convey information from the gut to the brain. It is known that fecal microbiome transplant (FMT) has been useful in treating several illnesses, including several mental illnesses. The investigators intend to deliver FMT to individuals with AN to determine the extent to which this modifies their GM, their biochemistry, their thinking processes and their moods and emotions. The investigators believe this will illuminate important aspects of AN that keep the illness in place, and that this will uncover useful approaches to better treat it.

Read the detailed description

The overall objective is to determine FMT's acceptability and the extent and means by which it helps patients with AN, restricting type. The investigators hypothesize that FMT will lead to diversification of the GM, improved metabolic and immunological status and reduced cognitive and psychiatric symptoms in patients with AN, details never investigated before. This will be due to FMT's ability to impart healthy microorganisms into the lower intestines and, thereby, improve GBM-axis signaling that may contribute to maintaining AN. The investigators propose that this will result in measurable improvement in cognitive distortions about weight, leading to reduced AN symptomatology, breaking the weight loss/AN cycle.

Specific Aims \& Hypotheses

This is a one-group, pre-/post-intervention trial of FMT in AN-restricting type, with 1-week, 3-week and 3-month follow up, administered before specialized eating disorders treatment. The hypotheses are:

  1. FMT will result in a sustained increase diversity of microbes with the metabolomic characteristics of increased short-chain fatty acids and bacteriophage composition compared with pre-treatment, as determined by targeted metabolomic approaches.
  2. FMT will improve immune profiles, reducing IL6, IL1b and the proportion of Th17 cells, along with an increase in repair cytokines such as TARC, IL4, IL13 and BDNF and Th2 cells.
  3. FMT will significantly improve cognitive and affective functioning, including task-switching efficiency, food aversion and obsessional thinking about weight, punishment and reward sensitivity, depression and anxiety symptomatology, and AN symptom severity.

This is a prospective, longitudinal, single-arm, pre-post intervention. Variables will be compared using repeated-measures analyses with each participant as their own comparator.

03

Conditions studied

  • Anorexia Nervosa

Keywords

  • Microbiome
  • Fecal transplant
  • Gut microbiome
  • Gut brain axis
  • Mental health
  • Eating Disorders
04

Who can participate

Ages eligible
16 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants in this study will be awaiting treatment for anorexia nervosa at London Health Sciences Centre's (LHSC, Ontario Canada) Adult Eating Disorders Service (AEDS).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • meet DSM 5 criteria for AN, restricting type, moderate or higher severity, as indicated by a \<17
  • Participants must we willing and able to swallow FMT capsules without vomiting
  • Able to read and understand conversational English

Exclusion criteria

Exclusion Criteria:

  1. Medical or psychiatric instability needing hospitalization
  2. Patients with AN binge/purge type
  3. Use of antibiotics or probiotics in the month prior to treatment
  4. Regular oral use, or potent topical steroid use on large sections of skin
  5. Chronic immune compromise and chronic illness affecting the intestinal tract or metabolic health
  6. Pregnancy or intended pregnancy over the time of study
  7. Patients enrolled in any treatment program that involves refeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Active treatment

    Receiving FMT

06

What researchers measure

Primary outcomes

  1. Feasibility of Intervention

    Success will be evaluated using recruitment and retention rates, adverse event rates, and missing data rates. Scores at 75% or above will indicate high tolerability for this population that is in desperate need of additional intervention options.

    Time frame: 1, 3, and 12 weeks post intervention

Secondary outcomes

  1. Shannon's Diversity Index

    Metric of microbiome diversity that considers richness of number of species and abundance. Higher values indicate more diversity. A value of 0 indicates that a community only has one species.

    Time frame: Pre-intervention, 12 weeks post-intervention

  2. Activated blood cells producing Th17/Th2 cytokines

    Activated blood cells producing Th17/Th2 cytokines by Luminex - IL6, IL1b, IL17, IL4, IL13 to evaluate immune responses.

    Time frame: Pre-intervention, and 12-weeks post intervention

  3. Activated blood cells producing BDNF

    Activated blood cells producing BDNF measured by Enzyme-Linked Immunosorbent Assay (ELISA)

    Time frame: Pre-intervention and 12-weeks post-intervention

  4. RNA levels

    RT-PCR (reverse transcription-polymerase chain reaction) for RNA levels of CCR6, CRTh2, CCR4, CXCR5 (marker genes for Th17 and Th2 cells)

    Time frame: Pre-intervention and 12-weeks post-intervention

  5. Task-switching Efficiency

    -Task-switching efficiency measured using the Cued Color-Shape Switching Task, CCSST. Accuracy and response time will be computed on both single-task blocks and mixed task blocks, where participants will need to switch between colour and shape responses. Switch costs and mixing costs will be calculated from these scores.

    Time frame: Pre-intervention, and 12 weeks post-intervention

  6. Punishment sensitivity and reward sensitivity

    Punishment sensitivity and reward sensitivity using the Behavioural Inhibition System/Behavioural Activation System Scales (BIS/BAS). There are three BAS scales in which higher scores equate to greater sensitivity to reward. There is one BIS scale for which higher scores equate to greater sensitivity to punishment.

    Time frame: Pre-intervention and 12-weeks post-intervention

  7. Depression

    Depression evaluated using the Montgomery Asberg Depression Rating Scale (MADRS). It is a 9-item scale where higher score indicates more severe depressive symptoms.

    Time frame: Pre-intervention, and at 1-, 3-, 12-weeks post intervention

  8. Depression

    Depression assessed with the Patient Health Questionnaire (PHQ-9), a 9-item scale evaluating the severity of depressive symptoms. Higher scores indicate more severe symptomatology.

    Time frame: Pre-intervention, and at 1-, 3-, 12-weeks post intervention

  9. Anxiety

    Anxiety assessed using the Spielberger State/Trait Anxiety Inventory (STAI)

    Time frame: Pre-intervention, and at 1-, 3-, 12-weeks post intervention

  10. Anxiety

    Anxiety assessed by the Generalized Anxiety Disorder 7-item scale (GAD-7)

    Time frame: Pre-intervention, and at 1-, 3-, 12-weeks post intervention

  11. Eating Attitudes

    -Food aversion and obsessional thinking about weight using the Eating Attitudes Test (EAT-26)

    Time frame: Pre-intervention, and 1-, 3-, 12-weeks post intervention

  12. Anorexia Nervosa Symptoms

    AN symptom severity with the Eating Disorders Examination Questionnaire (EDE-Q)

    Time frame: Pre-intervention, and at 1-, 3-, 12-weeks post intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — This is a small feasibility study. While we would not make personally identifiable information public, even the basic demographic information could be used to re-identify a participant. In light of the nature of this study we do not feel it is in the interest of our participants to share data on a repository.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.

Of 56 non-industry observational studies under Anorexia Nervosa, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 11 months is below that.

Counting every sponsor, half of 56 studies reached it within 38 months; a quarter within 16 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Aug 27, 2025
StartEst.
Jan 15, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Aug 31, 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07143981
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Jan 15, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Michael Wammes
Contact
michael.wammes@lhsc.on.ca
519-646-6000 ext. 65196
Medina Meddaoui
Contact
medina.meddaoui@lhsc.on.ca
Elizabeth Osuch
principal investigator · London Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion